Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index; 32 of the 40 sources its claims cite were checked for support.

Linkage, whole genome sequence, and biological data implicate variants in RAB10 in Alzheimer’s disease resilience

Open access

Abstract

BACKGROUND: While age and the APOE ε4 allele are major risk factors for Alzheimer's disease (AD), a small percentage of individuals with these risk factors exhibit AD resilience by living well beyond 75 years of age without any clinical symptoms of cognitive decline. METHODS: We used over 200 "AD resilient" individuals and an innovative, pedigree-based approach to identify genetic variants that segregate with AD resilience. First, we performed linkage analyses in pedigrees with resilient individuals and a statistical excess of AD deaths. Second, we used whole genome sequences to identify candidate SNPs in significant linkage regions. Third, we replicated SNPs from the linkage peaks that reduced risk for AD in an independent dataset and in a gene-based test. Finally, we experimentally characterized replicated SNPs. RESULTS: Rs142787485 in RAB10 confers significant protection against AD (p value = 0.0184, odds ratio = 0.5853). Moreover, we replicated this association in an independent series of unrelated individuals (p value = 0.028, odds ratio = 0.69) and used a gene-based test to confirm a role for RAB10 variants in modifying AD risk (p value = 0.002). Experimentally, we demonstrated that knockdown of RAB10 resulted in a significant decrease in Aβ42 (p value = 0.0003) and in the Aβ42/Aβ40 ratio (p value = 0.0001) in neuroblastoma cells. We also found that RAB10 expression is significantly elevated in human AD brains (p value = 0.04). CONCLUSIONS: Our results suggest that RAB10 could be a promising therapeutic target for AD prevention. In addition, our gene discovery approach can be expanded and adapted to other phenotypes, thus serving as a model for future efforts to identify rare variants for AD and other complex human diseases.

Overview

CoChat Summary

TL;DR

This study used AD-resilient pedigrees, linkage, whole-genome sequencing, replication, and in vitro experiments to implicate rare RAB10 variation in protection against Alzheimer’s disease. The strongest evidence centered on rs142787485, which was associated with reduced AD risk and with lower Aβ42/Aβ40 after RAB10 knockdown.

Key findings

  • Rs142787485 in RAB10 was associated with significant protection against AD (p = 0.0184, OR = 0.5853) and replicated in an independent unrelated series (p = 0.028, OR = 0.69); a gene-based test also supported RAB10 variants modifying AD risk (p = 0.002).
  • Knockdown of RAB10 significantly decreased Aβ42 (p = 0.0003) and the Aβ42/Aβ40 ratio (p = 0.0001) in neuroblastoma cells, while RAB10 overexpression increased the Aβ42/Aβ40 ratio (p = 0.0133).
  • RAB10 expression was significantly elevated in human AD brains (p = 0.04 in the abstract; Mayo Clinic temporal cortex Simple Model p = 6.96E-09, q = 1.50E-06).
  • SAR1A did not replicate in the CCS (p = 0.26, OR = 0.87) and its gene-based test was not significant (p = 1.00); SAR1A functional results were inconclusive.

Methods

  • Pedigree-based discovery: Utah Population Database pedigrees with excess AD mortality plus at least four AD-resilient individuals and four AD cases; linkage analysis with MCLINK identified suggestive peaks on chromosome 2 (TLOD 2.21) and chromosome 10 (TLOD 2.10).
  • Samples and sequencing: 232 AD-resilient individuals from the Cache County Study (≥75 years, cognitively normal, ≥1 APOE ε4 allele; 135 females, 97 males, mean age 81), WGS for 212 at ~40×, plus 581 AD cases; validation used the Alzheimer’s Genetic Analysis Group, CCS, and ADNI, with SNP association and SKAT-O gene-based tests.
  • Functional and expression work: RAB10 and SAR1A overexpression/knockdown in N2A695 cells with ELISA and immunoblotting; RNAseq expression analyses in 80 AD vs 76 control Mayo Clinic brains and public AD brain datasets.

Limitations

  • The paper states that pedigree selection and rarity of AD-resilient samples made significant LOD scores difficult; only suggestive LOD scores were obtained in two of five pedigrees, with no significant LOD scores in any pedigree.
  • The paper states that AD affection status relied on ICD9/ICD10 codes on Utah death certificates, which likely undercounts AD deaths and makes estimates conservative; genealogy data may include non-biological or censored relationships, and Utah European-descent results may not generalize.
  • The paper states that SAR1A knockdown was only modest and its functional data were inconclusive; evident from the text, the discovery approach selected only one candidate SNP from each linkage peak for further analysis, and the SAR1A variant did not replicate.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/s13073-017-0486-1

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Overview of the process followed for analysis of data in this project. TLOD theta LOD, UPDB Utah Population Database, CCS Cache County Study on Memory Health and Aging, AGAG Alzheimer’s Genetics Analysis Group, ADNI Alzheimer’s Disease Neuroimaging Initiative. *Although eight variants passed all filters, two representative variants (one from each pedigree) were chosen based on known biology of the genes they reside in
Fig. 1 Overview of the process followed for analysis of data in this project. TLOD theta LOD, UPDB Utah Population Database, CCS Cache County Study on Memory Health and Aging, AGAG Alzheimer’s Genetics Analysis Group, ADNI Alzheimer’s Disease Neuroimaging Initiative. *Although eight variants passed all filters, two representative variants (one from each pedigree) were chosen based on known biology of the genes they reside inCC BY · PubMed Central
Fig. 2 Sar1a subtly affects APP processing in vitro. a Full-length APP levels are not altered by Sar1a expression. Immunoblots of N2A695 cells transiently transfected with vectors expressing GFP, Sar1a, scrambled shRNA, or shRNA specific to Sar1a. Open arrowhead, APP; closed arrowhead, CTF-β and CTF-ɑ. b Sar1a expression does not significantly alter extracellular amyloid-beta levels. Conditioned media from N2A695 cells overexpressing or silencing Sar1a were analyzed by ELISA and resulting values were expressed relative to control. c Sar1a expression does not significantly alter sAPP levels. Quantification of immunoblots of sAPPalpha, sAPPbeta, and sAPPtotal. d Sar1a overexpression alters CTF-β and CTF-ɑ. Quantification of immunoblots of full-length APP, CTF-β, and CTF-ɑ. Graphs represent mean ± SEM from at least three independent experiments. *p value < 0.05
Fig. 2 Sar1a subtly affects APP processing in vitro. a Full-length APP levels are not altered by Sar1a expression. Immunoblots of N2A695 cells transiently transfected with vectors expressing GFP, Sar1a, scrambled shRNA, or shRNA specific to Sar1a. Open arrowhead, APP; closed arrowhead, CTF-β and CTF-ɑ. b Sar1a expression does not significantly alter extracellular amyloid-beta levels. Conditioned media from N2A695 cells overexpressing or silencing Sar1a were analyzed by ELISA and resulting values were expressed relative to control. c Sar1a expression does not significantly alter sAPP levels. Quantification of immunoblots of sAPPalpha, sAPPbeta, and sAPPtotal. d Sar1a overexpression alters CTF-β and CTF-ɑ. Quantification of immunoblots of full-length APP, CTF-β, and CTF-ɑ. Graphs represent mean ± SEM from at least three independent experiments. *p value < 0.05CC BY · PubMed Central
Fig. 3 Rab10 alters APP processing in vitro. a Full-length APP levels are not altered by Rab10 expression. Immunoblots of N2A695 cells transiently transfected with vectors expressing GFP, Rab10, scrambled shRNA, or shRNA specific to Rab10. Open arrowheads, APP; closed arrowheads, CTF-β and CTF-ɑ. b Rab10 expression alters extracellular amyloid-beta levels. Conditioned media from N2A695 cells overexpressing or silencing Rab10 were analyzed by ELISA and resulting values were expressed relative to control. c Rab10 expression does not significantly alter sAPP levels. Quantification of immunoblots of sAPPalpha, sAPPbeta, and sAPPtotal. d Rab10 overexpression alters CTF-β. Quantification of immunoblots of full-length APP, CTF-β, and CTF-ɑ. Graphs represent mean ± SEM from at least three independent experiments. *p value < 0.05
Fig. 3 Rab10 alters APP processing in vitro. a Full-length APP levels are not altered by Rab10 expression. Immunoblots of N2A695 cells transiently transfected with vectors expressing GFP, Rab10, scrambled shRNA, or shRNA specific to Rab10. Open arrowheads, APP; closed arrowheads, CTF-β and CTF-ɑ. b Rab10 expression alters extracellular amyloid-beta levels. Conditioned media from N2A695 cells overexpressing or silencing Rab10 were analyzed by ELISA and resulting values were expressed relative to control. c Rab10 expression does not significantly alter sAPP levels. Quantification of immunoblots of sAPPalpha, sAPPbeta, and sAPPtotal. d Rab10 overexpression alters CTF-β. Quantification of immunoblots of full-length APP, CTF-β, and CTF-ɑ. Graphs represent mean ± SEM from at least three independent experiments. *p value < 0.05CC BY · PubMed Central

Verification

Claims the paper makes

15 Valid · 9 Not valid · 3 Not checked · 76 Own results and interpretations

48 more claims · 1 with their cited sources checked

Create a free account to see all 103 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 20
  • Probably not a substantial claim. 38

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

4 of 4

Citations

Cites

Show all 60 references

Research works printed but not linked: 2

  1. Skolnick M. The Utah Geneological database: a resource for genetic epidemiology. In: Cairns J, Lyons J, Skolnick M, editors. Banbury Report No 4: Cancer incidence in defined populations. New York: Cold Spring Harbor Laboratory Press; 1980. p. 285–97.
  2. Murray C. U.S. Patterns of mortality by county and race: 1965-1994. Cambridge: Harvard Center for Population and Development Studies; 1998.

Cited by

See all 87

Metadata

Authors
Initiative, F. T. A. D. N., Ridge, P. G., Karch, C. M., Hsu, S., Arano, I., Teerlink, C. C., Ebbert, M. T. W., Gonzalez Murcia, J. D., Farnham, J. M., Damato, A. R., Allen, M., Wang, X., Harari, O., Fernandez, V. M., Guerreiro, R., Bras, J., Hardy, J., Munger, R., Norton, M., Sassi, C., Singleton, A., Younkin, S. G., Dickson, D. W., Golde, T. E., Price, N. D., Ertekin-Taner, N., Cruchaga, C., Goate, A. M., Corcoran, C., Tschanz, J., Cannon-Albright, L. A., & Kauwe, J. S. K.
Affiliations
  • Brigham Young University (US)
  • Washington University in St. Louis (US)
  • Mayo Clinic (US)
  • UCL Queen Square Institute of Neurology (GB)
  • Utah State University (US)
  • National Institutes of Health (US)
  • Institute for Systems Biology (US)
Corresponding author
Kauwe, John S. K.
Venue
Genome Medicine
Published
2017-11-29
Volume
9
Issue
1
Pages
100-100
ISSN
1756-994X (ISSN-L)
OpenAlex
W2768955389
Cited by
83
References
60
Citations by year
2026: 3 · 2025: 7 · 2024: 13 · 2023: 4 · 2022: 12 · 2021: 12 · 2020: 14 · 2019: 9 · 2018: 9
FWCI
6.48
Type
journal article
Language
en
Open access
Licence
Locations
  • Genome Medicine (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, other-oa)
  • University of Florida Digital Collections (University of Florida) (submittedVersion, other-oa)
  • Digital Commons - USU (Utah State University) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • UCL Discovery (University College London) (submittedVersion)
Funders
  • National Institute on Aging (RF1AG054052, U01AG052411)
  • National Institute of Neurological Disorders and Stroke (R01NS080820)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
Keywords
Alzheimer's disease, Rab10, genetic linkage, rare variants, APOE ε4, amyloid-beta 42, Aβ42/Aβ40 ratio, neuroblastoma cells, gene knockdown, therapeutic target
MeSH terms
Aged, 80 and over, Alzheimer Disease, Animals, Brain, Female, Humans, Male, Gene Expression, Genetic Predisposition to Disease, Monomeric GTP-Binding Proteins, Polymorphism, Single Nucleotide, rab GTP-Binding Proteins, Cell Line, Tumor, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-11-08, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-08 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Linkage, whole genome sequence, and biological data implicate variants in RAB10 in Alzheimer’s disease resilience. https://app.cochat.ai/papers/10.1186/s13073-017-0486-1
The paper
Initiative, F. T. A. D. N., Ridge, P. G., Karch, C. M., Hsu, S., Arano, I., Teerlink, C. C., Ebbert, M. T. W., Gonzalez Murcia, J. D., Farnham, J. M., Damato, A. R., Allen, M., Wang, X., Harari, O., Fernandez, V. M., Guerreiro, R., Bras, J., Hardy, J., Munger, R., Norton, M., . . . Kauwe, J. S. K. (2017). Linkage, whole genome sequence, and biological data implicate variants in RAB10 in Alzheimer’s disease resilience. Genome Medicine. https://doi.org/10.1186/s13073-017-0486-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.